Skip to main content
S&P 5007,549.94+2.35%DOW52,389.75+2.15%NASDAQ25,253.14+2.74%BTC$74,996.00-0.09%ETH$2,124.96-0.71%GOLD$4,142.60+0.68%OIL$85.95-1.04%
Smart Investors Daily
SID Premium
LE

NASDAQ · LENZ

LENZ Therapeutics, Inc.

Healthcare · Biotechnology

$4.29

Up+$0.79 (+22.57%)

Updated Nov 10, 2026, 5:02 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
684.09M
P/E ratio
-13.13
Dividend yield
0.00%
52-week range
$2.80 – $32.13
Volume
1.54M
Avg. volume
997.98K

Price performance · LENZ

LENZ price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 9, 2026

LENZ closed at $4.29 after 21 trading sessions, up 18.84% for the selected period.

Last close
$4.29
Period change
+18.84%
Period low
$3.01
Period high
$4.29
Daily close
View OHLC price history
LENZ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 9, 2026$3.57$4.37$3.40$4.291.54M
Nov 6, 2026$3.00$3.51$3.00$3.50785.67K
Nov 5, 2026$3.44$3.44$3.00$3.01737K
Nov 4, 2026$3.60$3.70$3.36$3.461.24M
Nov 3, 2026$3.04$3.73$3.04$3.501.57M
Nov 2, 2026$3.07$3.19$2.80$3.052.26M
Oct 30, 2026$3.38$3.425$3.04$3.052.26M
Oct 29, 2026$3.00$3.58$2.995$3.495.99M
Oct 28, 2026$3.10$3.2191$3.07$3.21573.9K
Oct 27, 2026$3.13$3.19$3.075$3.15377.75K
Oct 26, 2026$3.16$3.195$3.095$3.145389.15K
Oct 23, 2026$3.23$3.23$3.06$3.16696.46K
Oct 22, 2026$3.25$3.285$3.18$3.25435.47K
Oct 21, 2026$3.20$3.37$3.145$3.22943.35K
Oct 20, 2026$3.27$3.33$3.12$3.19819.37K
Oct 19, 2026$3.27$3.40$3.209$3.30648.75K
Oct 16, 2026$3.56$3.56$3.21$3.27939.08K
Oct 15, 2026$3.43$3.64$3.43$3.57793.85K
Oct 14, 2026$3.39$3.615$3.345$3.431.04M
Oct 13, 2026$3.62$3.62$3.395$3.40605.46K
Oct 12, 2026$3.64$3.71$3.60$3.61603.48K

Latest LENZ news

The latest Smart Investors Daily articles mentioning LENZ.

Stock researchCompany · Overview

LENZ research

Overview

Company profile and research snapshot.

Company profile

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$61.50
Implied upside
—
Analysts
—
LENZ recent ratings
DateFirmRatingTarget
Nov 5, 2026CitigroupBuy—
Oct 30, 2026HC Wainwright & Co.Buy—
Oct 29, 2026TD CowenBuy—
Oct 21, 2026TD CowenBuy—
Oct 19, 2026Piper SandlerNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Split On VIZZ

The fair value estimate for LENZ Therapeutics has been revised from US$23.57 to US$15.00, which materially changes how much upside some analysts see in the stock compared with earlier assumptions. That reset lines up with recent research on VIZZ, where opinions are split between analysts who still see room for upside from execution and others who are more focused on launch risks and leadership changes. As you read on, you will see how these shifting price targets fit into the broader analyst...

Yahoo · Oct 30, 2026

LENZ Therapeutics (LENZ) Stock Rallies As Q3 Results Expose Cash Burn

LENZ Therapeutics came into this Q3 2026 report with a bruised share chart, down sharply over the past three months. The stock then popped 8.7% to US$3.49 on the first full trading day after earnings. The story traders bought into was simple. Product revenue reached US$2.6 million on roughly 38,000 paid prescriptions for its presbyopia eye drop, while the business still posted a net loss of about US$31 million. That gap between early commercial traction and heavy cash burn now sits at the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By